{"nctId":"NCT02289963","briefTitle":"Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan","startDateStruct":{"date":"2015-01"},"conditions":["Hypercholesterolemia"],"count":199,"armGroups":[{"label":"Placebo Q2W","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo (for Alirocumab)","Drug: Lipid-Modifying Therapy (LMT)"]},{"label":"Alirocumab 75 mg Q2W/Up to 150 mg Q2W","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Alirocumab","Drug: Lipid-Modifying Therapy (LMT)"]}],"interventions":[{"name":"Placebo (for Alirocumab)","otherNames":[]},{"name":"Alirocumab","otherNames":["SAR236553","REGN727","PraluentÂ®"]},{"name":"Lipid-Modifying Therapy (LMT)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\nParticipants with hypercholesterolemia and established coronary heart disease (CHD) or CHD risk equivalents who are not adequately controlled with a maximally tolerated daily dose of statin with or without other LMT, both at stable dose for at least 4 weeks prior to screening visit (Week -3).\n\nExclusion criteria:\n\n* Aged \\<18 years or legal age of adulthood, whichever was greater.\n* Participants without established CHD or CHD risk equivalent.\n* LDL-C \\<70 mg/dL (\\<1.81 mmol/L) in participants with a history of documented cardiovascular disease.\n* LDL-C \\<100 mg/dL (\\<2.59 mmol/L) in participants without a history of documented cardiovascular disease.\n* Not on a stable dose of LMT (including statin) for at least 4 weeks prior to the screening visit (Week -3) or between screening to randomization visits.\n* Currently taking a statin other than atorvastatin, rosuvastatin or simvastatin.\n* Atorvastatin, rosuvastatin or simvastatin was not taken daily or not taken at a registered dose.\n* Daily doses above atorvastatin 80 mg, rosuvastatin 20 mg or simvastatin 40 mg.\n* Fasting serum triglycerides \\>400 mg/dL (\\>4.52 mmol/L) at the screening period.\n\nThe above information is not intended to contain all considerations relevant to a participants's potential participation in a clinical trial.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis","description":"Adjusted Least-squares (LS) means and standard errors at Week 24 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data up to Week 24 regardless of status on- or off-treatment were used in the model (ITT analysis).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":"2.9"},{"groupId":"OG001","value":"-57.1","spread":"3.0"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis","description":"Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data up to Week 24 (i.e. up to 21 days after last injection) (on-treatment analysis).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":"2.7"},{"groupId":"OG001","value":"-60.2","spread":"2.8"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including all available post-baseline data up to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":"2.2"},{"groupId":"OG001","value":"-57.9","spread":"2.2"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis","description":"Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including available post-baseline on-treatment data up to Week 24 (i.e. up to 21 days after last injection).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":"2.2"},{"groupId":"OG001","value":"-58.4","spread":"2.2"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including all available post-baseline data up to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":"2.3"},{"groupId":"OG001","value":"-42.3","spread":"2.4"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apo B at Week 24 - On-treatment Analysis","description":"Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data up to Week 24 (i.e. up to 21 days after last injection).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":"2.1"},{"groupId":"OG001","value":"-45.4","spread":"2.2"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including all available post-baseline data up to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":"2.4"},{"groupId":"OG001","value":"-47.2","spread":"2.5"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non-HDL-C at Week 24 - On-treatment Analysis","description":"Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data up to Week 24 (i.e. up to 21 days after last injection).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":"2.2"},{"groupId":"OG001","value":"-50.1","spread":"2.3"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including all available post-baseline data up to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":"1.8"},{"groupId":"OG001","value":"-31.2","spread":"1.8"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apo B at Week 12 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including all available post-baseline data up to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","spread":"1.8"},{"groupId":"OG001","value":"-40.9","spread":"1.8"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including all available post-baseline data up to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":"1.8"},{"groupId":"OG001","value":"-47.3","spread":"1.9"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Total-C at Week 12 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including all available post-baseline data up to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":"1.4"},{"groupId":"OG001","value":"-32.9","spread":"1.4"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis","description":"Adjusted percentages at Week 24 were obtained from multiple imputation approach model for handling of missing data. All available post-baseline data up to Week 24 regardless of status on- or off-treatment were included in the imputation model.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.2","spread":null},{"groupId":"OG001","value":"85.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-treatment Analysis","description":"Adjusted percentages at Week 24 were obtained from multiple imputation approach model including available post-baseline on-treatment data up to Week 24 (i.e. up to 21 days after last injection).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.1","spread":null},{"groupId":"OG001","value":"88.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis","description":"Adjusted means and standard errors at Week 24 were obtained from multiple imputation approach followed by robust regression model for handling of missing data. All available post-baseline data up to Week 24 regardless of status on- or off-treatment were included in the imputation model.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.251","spread":"2.962"},{"groupId":"OG001","value":"-35.862","spread":"3.011"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in High Density Lipoprotein (HDL-C) at Week 24 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including all available post-baseline data up to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.2","spread":"1.7"},{"groupId":"OG001","value":"13.8","spread":"1.8"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis","description":"Adjusted means and standard errors at Week 24 were obtained from multiple imputation approach followed by robust regression model including all available post-baseline data up to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.627","spread":"3.111"},{"groupId":"OG001","value":"-8.143","spread":"3.204"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 24 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including all available post-baseline data up to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"1.2"},{"groupId":"OG001","value":"4.5","spread":"1.2"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Lipoprotein(a) at Week 12- ITT Analysis","description":"Adjusted means and standard errors at Week 12 were obtained from multiple imputation approach followed by robust regression model including all available post-baseline data up to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.676","spread":"2.732"},{"groupId":"OG001","value":"-33.601","spread":"2.778"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including all available post-baseline data up to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"1.5"},{"groupId":"OG001","value":"7.1","spread":"1.6"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis","description":"Adjusted means and standard errors at Week 12 were obtained from multiple imputation approach followed by a robust regression model including all available post-baseline data up to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.113","spread":"3.192"},{"groupId":"OG001","value":"-6.999","spread":"3.252"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including all available post-baseline data up to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"1.1"},{"groupId":"OG001","value":"4.5","spread":"1.1"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":10,"n":102},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Dizziness","Headache","Diarrhoea"]}}}